Evidera (@evideraglobal) header
Evidera (@evideraglobal) profile picture

Evidera, a PPD business specializing in Evidence, Value, and Access

Global
Joined May 2014
Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)Photo by Evidera (@evideraglobal)
Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market. 📥 bit.ly/3syfvGd
2
2
271
Standing room only! 👏 Paulina Rolska-Wójcik and Jessica Griffiths, members of our value and access consulting team, presented a HEOR Theater session on the new EU HTA regulation in front of an overflow crowd at #ISPOREurope.
1
309
The first day of #ISPOREurope has been a huge success! Our staff in attendance snapped this group photo as they were preparing to welcome clients to the evening reception. Stop by and see us at booth C2-001 tomorrow!
232
We're just a few days away from #ISPOREurope! We're excited to attend this year's event with @corevitasdata, Thermo Fisher Scientific's latest acquisition that enhances our #RWD and #RWE solutions. Meet us at booth C2-001, or schedule a chat with us. » bit.ly/3u1tSnx
179
Market approval does not guarantee commercial or clinical success. Regulatory considerations, #patientadherence and inflexible clinical workflows can hinder product uptake. Our cutting-edge #implementationscience services can help address these barriers » bit.ly/3KcqStx
144
Join our webinar on 7 November to explore the benefits and challenges of collecting #realworlddata (RWD) in continued and #earlyaccessprograms. Register today! » bit.ly/3u2yvxk
115
How will new European Union (EU) health technology assessment (#HTA) regulations commencing in 2025 impact your cell and gene therapy (CGT) submission? We have your answers. » bit.ly/44NRZnz
117
Discover how #healtheconomic models play a pivotal role in product development, from early planning through analyses. Register for this upcoming expert webinar to gain valuable insights. » bit.ly/3rC31gV
1
107
With OncoLocator data, insights into cancer treatments are endless. Gaining a global understanding of standard of care. Evaluating #earlyphase assets and beyond. OncoLocator is more than data — it’s data smarter. 📈 bit.ly/3DnYfpj #realworldevidence #realworlddata
91
Many #noveltherapies fail to get integrated into real-world clinical practice. It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » bit.ly/3KcqStx
1
93
Regulation (EU) 2021/2282 commences in January 2025 for #oncology and #ATMPs and will be fully implemented by 2030. Discover how our value & access consultants can aid your European #marketaccess. » bit.ly/3Ecy85f
1
95
Gain real-time understanding of cancer treatment patterns with unmatched data relevance. ➠ bit.ly/3DnYfpj #realworlddata
89
Regulation (EU) 2021/2282 starts in January 2025 for #oncology and #ATMPs, with full implementation by 2030. Learn how our value & access consultants can help you prepare for market access in Europe. » bit.ly/3Ecy85f
120
Our iValue Suite™ helps create best-in-class value stories, global value dossiers, #HTA submissions, payer communication decks and objection handlers. Contact us today to schedule a demo. » bit.ly/45HcIsK
108
Donald Smith authored a white paper that defines the Pre-Approval Information Exchange (PIE) Act, compares it to the U.S. Food and Drug Administration (FDA) guidance, and outlines how implementation will support advancement of new therapies to market. 📥 bit.ly/3syfvGd
117
Our experts advise using a framework to assess options for transformative medicines in order to maximize the value of #IntegratedScientificAdvice. But, that's not always easy. Let our insights guide you. » bit.ly/3E4oPEk #patientaccess #consulting #scientificadvice
1
80
What is driving the future of #realworldevidence? Learn more from our blog, in which our thought leaders outline six key trends, including #realworlddata, #marketaccess, cross-industry collaboration initiatives and more. » bit.ly/43ZU6Tq
53
We’re excited to announce the completion of the acquisition of @corevitasdata. CorEvitas provides insight to the life sciences industry that improves patient care and clinical outcomes, and together we will expand our clinical research services.

5
16
3,782
OncoLocator™ examines geographic differences in treatment across the most prevalent cancer indications in #womenshealth. Would you like to explore more? Contact us for a free flat file sample and demo presentation. » bit.ly/47nAL1t #niraparib #olaraparib #bevacizumab
92
Many #noveltherapies fail to get integrated into real-world clinical practice. It's important to conduct a contextual analysis to understand the factors that could affect uptake, adoption and sustained use of a new therapy or health care technology. » bit.ly/3KcqStx
73